Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S ALLEGRA ALLERGY versus DIPHENHYDRAMINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S ALLEGRA ALLERGY versus DIPHENHYDRAMINE HYDROCHLORIDE.
CHILDREN'S ALLEGRA ALLERGY vs DIPHENHYDRAMINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexofenadine is a selective peripheral H1-receptor antagonist. It inhibits histamine release from mast cells and basophils, reducing allergic symptoms.
Competitive antagonist of histamine H1 receptors, reducing allergic symptoms; also exerts anticholinergic, sedative, and antiemetic effects via central and peripheral receptor blockade.
Fexofenadine 60 mg orally twice daily or 180 mg once daily.
25-50 mg orally or intramuscularly every 4-6 hours as needed; maximum 300 mg per day.
None Documented
None Documented
Terminal elimination half-life is approximately 14.4 hours (range 11–17 hours) in healthy adults. In children aged 6–12 years, half-life is similar. Clinical context: allows once-daily dosing.
Terminal elimination half-life 4–10 hours (mean ~7 hours); prolonged in elderly, hepatic impairment, and with CYP2D6 poor metabolizers.
Fexofenadine is excreted primarily unchanged in feces (approximately 80%) and urine (approximately 11%). Biliary excretion accounts for a minor portion.
Renal elimination of metabolites accounts for ~60% of the dose; <5% excreted unchanged. Fecal excretion ~40% via bile.
Category C
Category A/B
Antihistamine
Antihistamine